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Based on this result, we decided to account for the 
differences in T stage, overall treatment time and 
concomitant treatment for the statistical analysis of outcome 
and toxicity. Mean follow up was 5.68 years in the group 
without ND and 5.83 years in the group with upfront ND. 
Local, regional and distant control after 2 years were 91.07% 
and 85.96% (p = 0.09), 89.22% and 83.27% (p = 0.12) and 
76.74% and 75.13% (p 0.92) in the group with and without 
upfront ND, respectively . We observed worse OS after 2 
years in the subgroup with upfront ND (48.01% vs. 70.79%, p = 
0.01). The difference in OS can be explained by more 
secondary primaries in this subgroup with upfront ND and 
more non-disease related deaths. We did not find a 
significant difference between both groups regarding edema 
and atrophy at 6, 12, 18 and 24 months (Figure 1). Regarding 
fibrosis, we found an overall trend towards worse outcome in 
the ND group at all time-points (p=0.06). A significantly 
higher proportion of severe fibrosis (grade ≥2) was present in 
the ND group (p=0.01) at all time points (Figure 1). 
 
 
 
Conclusion: Both treatment regimens have a comparable 
local, regional and distant control. However, fibrosis and 
more specifically fibrosis grade ≥2 is more prominent 
following upfront ND and CRT when compared to CRT alone.  
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Purpose or Objective: Chemo-radiotherapy (CRT) plays a 
major role in the management of patients with locally 
advanced squamous cell carcinoma of head and neck (LA-
SCCHN). However, loco-regional (LR) failure remains a 
significant problem due to the resistance to radiotherapy and 
chemotherapy. Inhibitors of Apoptosis Proteins (IAPs) are 
expressed in various cancers and are able to block caspase 
activation and modulate NF-kB signalling pathways. As such, 
they represent attractive targets to overcome resistance to 
both chemo- and radio-therapy. Debio 1143 is a potent 
orally-available IAP antagonist currently in clinical 
development able to radiosensitize and ameliorate the 
effects of platinum derivatives in multiple SCCHN models 
both in vitro and in vivo. A previous phase I study showed 
Debio 1143 as a single agent was well tolerated up to 400 
mg/day q14d21. This Phase I study defined the dose limiting 
toxicities (DLTs), maximum tolerated dose (MTD), safety, 
pharmacokinetic (PK) and pharmacodynamic (PD) of Debio 
1143 in combination with CRT. 
 
Material and Methods: Treatment-naïve LA-SSCHN (stage 
III/IV), negative HPV status for oropharynx, were treated 
with CRT (70 Gy in 7 weeks + cisplatin 100 mg/m2 every 3 
weeks) and escalating doses of Debio 1143, administered 
orally once daily on days 1-14 every 3 weeks for a maximum 
of 3 cycles. The starting dose of Debio 1143 was 100 mg/day. 
Doses were escalated using a Bayesian Continuous 
Reassessment Method (CRM) until MTD, based on dose 
limiting toxicities (DLTs) observed within the first 9 weeks 
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from start of study drug administration. Dose escalation 
decision and recommended dose (RD) were made by an 
independent safety committee. Blood PK and PD samples 
were serially drawn along the 3 cycles. 
 
Results: Fourteen patients were included in the study. DLTs 
per dose level (DL) are shown in the table with 3 patients 
experiencing more than one DLT. The RD of Debio 1143 to be 
combined with CRT was 200 mg/day (=MTD). Debio 1143 
exposure increased proportionally with dose and did not 
accumulate over time. Amylase/lipase and ALT/AST increase 
was associated with higher Debio 1143 exposures. At all dose 
levels, the PD effect of Debio 1143 was evidenced by the 
degradation of cIAP1 in PBMCs and a trend in an increase of 
serum MCP1. 12 patients were evaluable for response by 
RECIST 10-12 weeks post treatment among which 3 CR, 5 PR 
and 1 SD.  
 
 
Conclusion: Combination of Debio 1143 with CRT was 
tolerated, exhibited favourable PK in combination with CRT 
with significant PD activity. The MTD was found to be 200 
mg/day and is now being used in a randomized phase 2 study 
initiated by GORTEC to evaluate the anti-tumor activity of 
this combination in LA-SCCHN. 
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Purpose or Objective: Study of pharmacokinetics (PK), 
toxicity, and compliance with nimorazole (NIM) which is 
currently investigated for its efficacy in three large 
randomized clinical trials (NIMRAD, EORTC 1219/DAHANCA 
29, and DAHANCA 30) 
 
Material and Methods: The PK of NIM was studied in 63 
patients with HNSCC treated in the DAHANCA-5 trial. While 
the toxicity and compliance were studied in HNSCC patients 
treated with NIM, in combination with radiotherapy (RT) or 
chemo-radiotherapy (CRT), in Denmark between 1990 and 
2013. Plasma concentration measurements were done using 
high pressure liquid chromatography following the first day 
dose; and plasma concentration profiles were subjected to 
non-compartmental PK analysis using validated PC-based 
software. The different PK parameters were calculated and 
correlated with the different patient- and treatment-related 
variables. Nimorazole was administered as oral tablets in 
doses of approximately 1.2 g/m² BSA before the first daily 
radiation treatment. A second dose of 1 g was given before 
the second RT fraction in the accelerated fractionation 
regimen (6 fractions/week). The compliance was estimated 
as the percentage of the initially prescribed dose; and drug-
related side effects were reported from the DAHANCA 
database. 
 
Results: A linear relationship between peak plasma 
concentration and administered dose was detected. The 
mean peak concentration was 36.8 ± 1.3 µg/ml, and the time 
of peak concentration ranged between 30 and 180 min 
(median 60 min). Plasma elimination occurred with a mean 
half-life of 3.35 ± 0.09 h. There was a statistically significant 
correlation between area under the concentration-time curve 
(mean 191 ± 6 µg·h/ml) and administered dose, especially 
when expressed as g/m². A statistically significant longer 
elimination half-life in men relative to women (mean 
difference 0.40 h; 95% confidence interval 0.77-0.03; P 0.03) 
was detected. A total of 1049 patients were investigated for 
toxicity and compliance with NIM. The compliance was fair, 
with both conventional and accelerated RT as well as CRT 
schedules, with 58% of patients received the full prescribed 
total dose. Nausea and vomiting were the major complaints 
representing 87% of the known side effects that caused dose 
reduction. All side effects ceased when treatment was 
interrupted, and neither severe nor long lasting side effects 
were observed. Female patients, and patients received 
accelerated CRT were significantly less compliant with NIM, 
and more likely to have nausea and vomiting; while patients 
who received less than 1100 mg/m² per day were 
significantly more compliant, and less likely to have nausea 
and vomiting. 
 
Conclusion: The current nimorazole administration practice 
in clinical trials is acceptable, and the compliance to the 
drug is fair, either with the conventional or accelerated RT as 
well as CRT, with tolerable acute, but neither persistent nor 
late, toxicity. 
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Purpose To demonstrate that dose painting (DP) is a 
promising tool to decrease overall treatment time (OTT), to 
reduce toxicity, to improve palliation or enhance tumor 
control. The present state of DP will be illustrated through 3 
types of applications. We will also speculate about the 
potential of DP to integrate with novel systemic treatment 
approaches.  
Materials and methods  
A. Topographical DP (TDP) in breast irradiation. TDP 
distributes dose as function of the spatial distribution of 
subclinical cancer deposits nearby the primary tumor in 
breast cancer. Patients (n=170) were randomized between 
prone whole breast irradiation (WBI) followed by a boost 
(WBI-SeqB: OTT=4 weeks) and WBI with simultaneous 
integrated boost (SIB) using TDP (WBI-TDP-SIB: OTT=3 
weeks). Acute moist desquamation rate was the primary 
endpoint.  
B. DP against bone metastasis pain. There is no dose-response 
relationship above 8 Gy single dose for the control of pain by 
uncomplicated bone metastases. This observation triggered 
the hypothesis that cytokine cascades counteracting 
palliation are activated by radiation and that their activity is 
function of the irradiated volume. DP was employed to 
drastically reduce the irradiated volume. Patients (n=45) 
were randomly assigned (1:1:1) to receive a single fraction of 
either 8 Gy with conventional radiotherapy (Conv-8Gy) or 8 
Gy with DP (dose range 6-10 Gy) (DP-8Gy) or 16 Gy with DP 
(dose range 14-18 Gy) (DP-16Gy). The trial was designed for 
selection of the experimental arm worthwhile of continuing 
in phase III.  
C. DP in loco-regionally advanced head&neck cancer. 18F-
FDG-PET-guided DP-treated patients enrolled in 3 dose-
escalation studies (n = 72) were matched with standard IMRT-
treated patients (n=72) irradiated during the same time 
period. Median dose in the DP-group was 70.2-85.9 Gy/30-32 
